{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:01:34Z","timestamp":1785214894239,"version":"3.55.0"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1055\/a-2679-4829","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:32:30Z","timestamp":1785191550000},"page":"813-821","source":"Crossref","is-referenced-by-count":0,"title":["Renale Komplikationen von Tumorimmuntherapien"],"prefix":"10.1055","volume":"151","author":[{"given":"Alban","family":"Avdiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Latus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"B Ibis","year":"2023","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Q Yin","year":"2023","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.13243","article-title":"Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor\u2010induced kidney disease","volume":"318","author":"H Seethapathy","year":"2023","journal-title":"Immunol Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"FB Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353339","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"P Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10157-023-02429-8","article-title":"Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer","volume":"28","author":"GA de Brito","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"S Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events","volume":"6","author":"B Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review","volume":"45","author":"R Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"A Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad292","article-title":"All-cause and immune checkpoint inhibitor\u2013associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality","volume":"17","author":"J-J Chen","year":"2024","journal-title":"Clin Kidney J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor\u2013Associated AKI: A Multicenter Study","volume":"31","author":"FB Cortazar","year":"2020","journal-title":"J Am Soc Nephrol JASN"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"MA Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series","volume":"76","author":"IA Strohbehn","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004421","article-title":"Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy","volume":"10","author":"ML Baker","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: A multicentre study","volume":"134","author":"O Nigro","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"DG Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010680","article-title":"Urine proteomics defines an immune checkpoint-associated nephritis signature","volume":"13","author":"JP Long","year":"2025","journal-title":"J Immunother Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.kint.2025.05.029","article-title":"Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor\u2013associated acute interstitial nephritis","volume":"108","author":"S Gupta","year":"2025","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"J Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"BJ Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI182275","article-title":"F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor\u2013associated acute kidney injury","volume":"134","author":"S Gupta","year":"2024","journal-title":"J Clin Invest"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future","volume":"29","author":"MA Perazella","year":"2018","journal-title":"J Am Soc Nephrol JASN"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"Disease Kidney","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A Systematic Review of Immune Checkpoint Inhibitor\u2013Associated Glomerular Disease","volume":"6","author":"A Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"N Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response","volume":"15","author":"V Parvathareddy","year":"2023","journal-title":"Cancers"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ekir.2025.10.018","article-title":"Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence","volume":"11","author":"N Youssef","year":"2026","journal-title":"Kidney Int Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor\u2013associated nephritis\u2014treatment standard","volume":"39","author":"E-B Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000538274","article-title":"Association of Proton Pump Inhibitor Use and Immune Checkpoint Inhibitor-Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes","volume":"55","author":"A Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jtct.2025.03.007","article-title":"Nephrotoxicity in CAR-T Cell Therapy","volume":"31","author":"K Sadowski","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40620-019-00691-2","article-title":"The renal adverse effects of cancer immunotherapy","volume":"33","author":"NC Steinel","year":"2020","journal-title":"J Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"E Dahl\u00e9n","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2147\/OTT.S465679","article-title":"Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies","volume":"17","author":"X Wen","year":"2024","journal-title":"OncoTargets Ther"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2679-4829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:46:32Z","timestamp":1785213992000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2679-4829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2679-4829","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}